Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov;41(11):5793-5802.
doi: 10.21873/anticanres.15396.

Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer

Affiliations
Clinical Trial

Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer

Masayuki Fujiwara et al. Anticancer Res. 2021 Nov.

Abstract

Background/aim: To evaluate the incidence and grade of radiation pneumonitis after volumetric modulated arc therapy (VMAT) performed for the treatment of non-small cell cancer (NSCLC).

Patients and methods: Fifty consecutive non-surgical candidates with NSCLC underwent VMAT. Thirty-five patients had stage-III tumors and 15 had recurrent tumors. The prescribed radiation dose for the gross tumor and the elective nodal area was 69 Gy in 30 fractions and 51 Gy in 30 fractions, respectively.

Results: Radiation pneumonitis developed in 38 patients (76%, 38/50), and grade ≥2 radiation pneumonitis developed in 11 patients (22%, 11/50). The percentage of lung volume that received a dose in excess of 5 Gy (V5), V10, V20, V30, and the mean lung dose (MLD) in the bilateral and ipsilateral lung were significantly associated with the development of grade ≥2 radiation pneumonitis.

Conclusion: The incidence and degree of radiation pneumonitis are acceptable following treatment of NSCLC with VMAT.

Keywords: IMRT; Non-small cell lung cancer; VMAT; chemoradiotherapy; radiation pneumonitis.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources